News Hub | News Direct

Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA

Kadimastem

Ness Ziona, Israel, January 22, 2024, Kadimastem (TASE: KDST) and iTolerance Inc. announced today that the companies held a preliminary meeting with the INTERACT committee of the U.S Food and Drug Administration (FDA) on January 19 th, 2024 regarding the preclinical and clinical development leading toward commercialization of iTOL-102, a potential cure for diabetes that does not require chronic immune system suppression. Before the meeting, the companies received a response document from the FDA noting important feedback about the current preclinical plans which the companies intend to use for the advancement of their potential joint collaboration development plans. With the feedback from the INTERACT meeting received, the companies are working on the design and commencement of a clinical study of iTOL-102 that is planned to be submitted to the FDA for an IND in the future. Dr. Anthony Japour, Chief Executive Officer of iTolerance, commented, “We are pleased with the continued progress of our research collaboration with Kadimastem. With the INTERACT meeting now complete and the feedback received from our discussions with FDA, we are evaluating next steps toward a potentially innovative cure for patients with Type 1 diabetes.” Kadimastem CEO Asaf Shiloni said, " Thanks to our scientific teams who presented the joint collaboration project in an impressive manner. I am convinced that the helpful meeting and the relevant feedback will contribute to the continued progress of our planned joint product development and hopefully provide a cure for those living with diabetes.” In May 2023, the companies announced their research collaboration agreement to co-develop and commercialize a breakthrough and innovative regenerative technology to cure diabetes without the need for chronic immunosuppression and received a grant in the aggregate amount of US$1.0 million from the Binational Israel-U.S. Industrial R&D (BIRD) Foundation. As part of the agreement, the companies are considering expanding their cooperation and advancing the development of iTOL-102. The joint project is based on Kadimastem’s diabetes product called IsletRx, which is comprised of clinical-grade clusters of human pancreatic islet like cells (ILCs). Preclinical studies have shown that the cells are able to detect the sugar levels in the body and to produce and secrete dependently, the required amounts of insulin and glucagon, just like a healthy pancreas. iTolerance, headquartered in Miami, Florida, has developed an innovative platform technology (iTOL-100) intended to enable the transplantation of allogeneic cells without tissue matching and without the need for chronic treatments that suppress the immune system of the transplant recipient (immunosuppression). This platform technology was successfully demonstrated in preclinical experiments in large animals (non-human primates), where diabetes was cured by allogeneic transplantation, without the need for long-term immunosuppressive treatments. About Kadimastem Kadimastem is a clinical stage cell therapy company, developing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications. IsletRx is the company's treatment for diabetes. IsletRx is comprised of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). About iTolerance, Inc. iTolerance is an early-stage privately-held regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without requiring life-long immunosuppression. Leveraging its proprietary biotechnology-derived Streptavidin-FasL fusion protein/biotin-PEG microgel (SA-FasL microgel) platform technology, iTOL-100, iTolerance is advancing a pipeline of programs using both allogenic pancreatic islets and stem cells that have the potential to cure diseases. Utilizing iTOL-100 to induce local immune tolerance, the Company is developing its lead indication as a potential cure for Type 1 Diabetes without the need for life-long immunosuppression. Additionally, the Company is developing iTOL-201 for treating liver failure by utilizing hepatocytes and iTOL-401 as a nanoparticle formulation for large organ transplants without the need for life-long immunosuppression. For more information, please visit itolerance.com. Forward Looking Statement This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under Kadimastem’s control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the company's activity, as well as developments in the general environment and external factors affecting the company's activity. The company's results and achievements in the future may differ materially from any presented herein and the company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the company's securities or an invitation to receive such offers. Investment in securities in general and in the company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Social Media: LinkedIn, Twitter, Facebook Contact Details Kadimastem Asaf Shiloni CEO s.bazak@kadimastem.com iTolerance Jenene Thomas Chief Executive Officer, JTC Team, LLC +1 833-475-8247 iTolerance@jtcir.com Susan Roberts +1 202-779-0929 sr@roberts-communications.com Company Website https://www.kadimastem.com/

January 22, 2024 07:33 AM Eastern Standard Time

Image

Trust & Will Bolsters Executive Team with Strategic Hires

Trust & Will

Trust & Will, the leading digital estate planning and settlement platform in the U.S., today announced that it has made a number of new executive hires amid significant revenue and member growth and future market opportunities. These notable hires include: Dale Sperling joins the company as Chief Marketing Officer, bringing a unique blend of leadership, creativity, and deep knowledge of brand and marketing to the new role. Dale has been a persistent force in the marketing world, most recently serving as CMO at Stash, a financial investing app, and previously held senior marketing roles at Walt Disney Internet Group and AOL. Doug Luftman joins the company as Chief Legal Officer to lead the legal, government affairs, and people operations groups and further elevate such functions as strategic business resources. Over his 25-year career, Doug has served in strategic roles spanning from General Counsel at startups to senior legal executive positions at companies such as DocuSign, CBS & Palm, Inc. Stephany Bader joins the company as VP of Product, to lead the product management and design organization, bringing over 15 years of product management experience to the role. She is responsible for setting the company’s product strategy and roadmap, as well as overseeing product execution and user experience design. Previously she led the investing product at Wealthfront, and held senior product leadership roles at Intuit, Eventbrite, and Google. Michael Jones joins the company as VP of Engineering to lead our engineering practice, bringing over 20 years of engineering leadership experience across fintech, startups, and communities. He has been accountable for building efficient teams from scratch and maturing organizations to scale across multiple engineering disciplines and cross-functional accountabilities. He most recently held senior engineering roles at Fundrise, Acorns, and Capital One. David Weisman was promoted to VP of Sales & Partnerships. He brings over 13 years of experience in partnerships and sales strategy and execution to his role. Previously, David held roles as Head of Business Development at Scoop Technologies and as Global Product Expert at Google, demonstrating expertise in B2B development, market analysis, and driving sustainable revenue growth. After recently announcing brand ambassadors Matthew and Kelly Stafford, along with becoming a Certified B Corporation, the startup is uniquely poised to help every family leave a legacy. "Empowering families to leave a lasting legacy is our mission. With top-tier talent joining our executive team, we're primed to reach the 60% of Americans without an estate plan through our affordable platform. As we gear up for explosive growth in 2024, their expertise and leadership align seamlessly with our vision. I'm confident their contributions will shape Trust & Will's future success," said Cody Barbo, Founder and CEO of Trust & Will. With more than 700,000 members, the digital platform has a 1300% growth rate according to Deloitte, and will reach even more families in 2024 to help with estate planning and probate. Squarely in hyper-growth mode, Trust & Will’s newly enhanced executive team will help propel the company through this next growth phase to serve hundreds of thousands of new members. ABOUT TRUST & WILL Trust & Will is simplifying estate planning and settlement with attorney-approved, legally valid documents and processes designed to adhere to individual state guidelines. Since 2017, we’ve helped hundreds of thousands of Trust & Will members leave their legacy with an affordable way to create an estate plan or settle the estate of a loved one. Our platform uses bank-level encryption that protects customer data and complies with the highest security standards, including SOC 2 and HIPAA. Trust & Will is a certified B Corporation and is the official estate planning benefit provider for AARP members, along with several leading financial institutions, who all believe in our mission of helping every family leave their legacy. Trust & Will is an online service providing legal forms and information. Trust & Will is not a law firm and does not provide legal advice. Contact Details Danielle Nuzzo +1 631-807-7772 danielle@trustandwill.com Company Website https://trustandwill.com

January 22, 2024 07:00 AM Eastern Standard Time

Mercury/13 Unveils Co-CEO Alliance: Mario Malavé and Victoire Cogevina Aim to Transform Women's Football Club Ownership

Mercury/13

London, January 22 nd, 2024 – ( Mercury/13 via 50NewsWire) -- Mario Malavé (31), a tech entrepreneur, Harvard and Forbes 30 Under 30 alum, and former VP of Sports Betting at Yahoo Sport s, will split CEO duties with Victoire Cogevina Reynal (32), a global advocate for women's football and former VP of Women’s Football at Onefootball. The collaboration marks an important step for Mercury/13 in its ambition to build the world’s leading multi-club ownership group in women’s football. Mario was previously the CEO and co-founder of Wagr, a sports betting startup acquired by Yahoo Sports in April 2023 that focused on making gaming social, safe, and accessible and was the first social sports betting operator to receive a license in the US. Following the acquisition, Mario became the VP of Sports Betting at Yahoo Sports and oversaw the full integration of his team. As Wagr’s CEO, Mario raised over $16M across three rounds and was backed by some of the world’s leading sports and technology investors, including: Seven Seven Six, led by Reddit co-founder Alexis Ohanian, Greycroft, Pear Ventures, BITKRAFT Ventures, the Kraft Group, owners of the New England Patriots and New England Revolution, Harris Blitzer Sports & Entertainment, owners of the Philadelphia 76ers and New Jersey Devils, among others. In joining Mercury/13, Mario is embracing a new challenge by venturing into women's football, citing it as an exciting opportunity to build in a space that has incredible potential and is close to both his and Victoire’s heart. The duo, who originally met in 2020 because they shared the same lead investor in their respective startups (Ohanian), are joined by the common belief that women’s football has an opportunity to grow itself more sustainably, creatively, and rapidly than the men’s game historically has. Their ambition is to establish Mercury/13 as a leading multi-club ownership group in women's football by acquiring club’s and supercharging their commercial viability. “Women's football is not just an exciting business opportunity; it's become an incredibly powerful gender equality movement. However, to succeed, we must shape its future not in opposition to men but in collaboration with them. Gender parity in leadership is not just an empty statement: both Mario and I want Mercury/13 to showcase what a diverse leadership team can achieve” said Victoire. “Mario’s world-class experience as an investor and founder, coupled with his deep passion and knowledge in football, made him the obvious partner to build Mercury/13 with,” she added. After overseeing the full integration of his team into Yahoo, Mario departed in October 2023 and joined Victoire Cogevina in the pursuit of a bold vision – redefining football club ownership by embracing a massive yet overlooked audience: women. "Unlike other investors in the space, we're intentionally focusing our efforts in Europe and Latin America, where we see more compelling risk-reward dynamics and valuations that are still lagging US comparables despite ample upside potential” said Mario. " As the recent growth in NWSL valuations has proven, investors can reset price expectations very quickly once they recalibrate their growth assumptions. We see all the right ingredients for something similar to happen in Europe if clubs and leagues can execute correctly. We want to help catalyze that growth in the markets we enter”. Drawing from their experience as successful startup founders in the sports space, Victoire and Mario are joining efforts to embark on a new journey together with conviction that women’s football is at an inflexion point that will transform the sport’s landscape. With an ambition to invest up to $100M over time, Mercury/13 is currently focusing its investment efforts in Europe and LatAm. The duo epitomizes a complementary leadership model, with each Co-CEO spearheading distinct facets of the organization. Malavé, with his background in business and investments, will oversee Mercury/13’s investments, business strategy, and football operations, while Cogevina will commandeer all commercial, marketing, and brand efforts across the portfolio. About Mario Malavé: A native of Caracas, Venezuela, Mario began his journey in the U.S. at 16. He graduated in 2013 with majors in Economics and Political Science magna cum laude. His first job was as an investment banker at Morgan Stanley, where he focused on cross-border M&A transactions across Latin America before transitioning to the firm’s renowned Technology Group in Menlo Park. Fascinated by technology and early-stage investing, Mario joined Playground Ventures, a deep-tech venture capital fund with $800M AUM, where he oversaw the execution of 40+ deals before pursuing an MBA at Harvard Business School. At HBS, Mario combined his passion for sports and entrepreneurship, leading a European Football trek and working with the Los Angeles Football Club. Before graduating, he co-founded Wagr, a venture-backed sports betting startup that raised over $16M from world-class investors and was acquired by Yahoo Sports in April 2023. Following the acquisition, Mario became the VP of Sports Betting at Yahoo Sports, making him one of the youngest VPs in the company. After overseeing his team’s integration, he joined Mercury/13 as a co-founder and co-CEO. About Mercury/13 Mercury/13 is a multi-club ownership group focused on acquiring controlling stakes in professional women's football teams in Europe and Latin America. The group aims to invest 100 million dollars in women’s football over the coming years. The vision is to become the industry standard of women’s football ownership, by identifying and investing in the next decade’s super clubs and fueling their commercial power to attract a massive, yet underserved, market: women. The group's acquisition strategy is based on the fundamental principle that women's football is a different game, and fans want a different experience. The name Mercury/13 is a tribute to the 13 women who were not allowed to work for NASA on the basis of their gender back in 1960. The program that would carry a spacecraft manned only by women was canceled in 1961. The authorities at the time did not believe that women alone could achieve the goal. Contact Details Mercury/13 Alejandra S Depalma +1 305-733-1313 Alejandra@mercury13.com

January 22, 2024 07:00 AM Eastern Standard Time

Image

Top NSFW AI Chatbots Ranking Review [Jan 2024]

500NewsWire

Discover the ultimate NSFW AI chat platforms that have been diligently ranked to enhance your online experiences. These AI-driven chatbots provide an adventurous opportunity for users to delve into their fantasies within a secure, judgment-free zone. The following review showcases the leading NSFW AI chatbots of January 2024, highlighting their innovative features to assist you in selecting the perfect match for your personal escapades. Table of Contents Introduction to NSFW AI Chatbots Top-Rated NSFW AI Chat Platforms AI: Premier NSFW AI Chat Experience NSFW Character AI: Unleashing Creativity in Chat Chai AI: A Formidable Alternate NSFW AI Chat My AI Girlfriend: Anime-Inspired NSFW Chat Adventures Janitor AI: A Quirky Spin on NSFW AI Chatbots Conclusion: Your Guide to Selecting NSFW AI Chat Platforms Frequently Asked Questions About NSFW AI Chatbots Introduction to NSFW AI Chatbots NSFW AI chatbots are specialized artificial intelligence systems created to engage users in conversations. These platforms offer a safe and non-judgmental environment for users to express and explore their deepest desires through conversation with AI. Top-Rated NSFW AI Chat Platforms CrushOn.AI: Premier NSFW AI Chat Experience Engaging Interaction: CrushOn.AI is a standout contender in the NSFW AI chatbot space, renowned for its ability to engage users in complex, dynamic conversations that transcend the typical chat experience. Diverse Models: Offering an array of models like the cutting-edge Llama2-13B-Uncensored and the imaginative Chronos-Hermes-13B, CrushOn.AI caters to a spectrum of interests and preferences. Customization at Your Fingertips: Users have the freedom to tailor their chatbot's personality, ensuring that every interaction is uniquely attuned to their desires. Community and Updates: With an active community and consistent updates, users are guaranteed an evolving chat experience. While its popularity is a testament to its quality, users may occasionally encounter server issues. The platform is also strictly for individuals above the age of 18 due to explicit content. 2. NSFW Character AI: Unleashing Creativity in Chat Creative Freedom: This platform is a haven for those who seek to express themselves without boundaries, offering an immersive NSFW chat environment where creativity knows no limits. Advanced Character Customization: With tools to craft and refine AI characters, users can breathe life into their imagined personas, enriching the intimacy of each conversation. Depth in Dialogue: Character AI NSFW doesn't just offer surface-level chit-chat; it's about deep, meaningful exchanges that push the boundaries of AI communication. Distinctive Personalities: The platform thrives on uniqueness, allowing users to interact with AI characters that are as individual as they are. 3. Chai AI: A Formidable Alternate NSFW AI Chat Unlimited NSFW Conversations: Chai AI offers an unbounded platform for NSFW discussions without restrictions. Custom Bot Development: The platform empowers users to craft and personalize their own bots, enhancing control over the chat experience. Diverse Bot Spectrum: Chai AI provides a wide range of bots to cater to various user needs and preferences. The free version comes with limited functionalities, and the subscription might be expensive for some users. 4. My AI Girlfriend: Anime-Inspired NSFW Chat Adventures Engaging Anime Experience: My AI Girlfriend offers an intimate chat experience with virtual anime characters, perfect for anime enthusiasts. Personalized Characters: Users can select from a range of anime characters that resonate with their personal taste, whether shy and cute or bold and adventurous. Versatile Functionality: These AI girlfriends provide emotional support, drama-free companionship, and confidence-boosting conversations. However, the platform is limited to anime characters and may occasionally deliver repetitive responses. 5. Janitor AI: A Quirky Spin on NSFW AI Chatbots Quirky NSFW Chats: Janitor AI offers a unique twist on NSFW AI chatbots, blending humor with conversational capabilities. Interactive User Experience: This platform ensures that each chat is entertaining and lively, thanks to its unconventional approach to NSFW AI chat. Personalized Themes: Users can choose themes and settings to match their mood, making each chat session a novel experience. The platform may not appeal to everyone due to its quirky nature and may lack the depth of more serious NSFW chatbots. Conclusion: Your Guide to Selecting NSFW AI Chat Platforms In the evolving landscape of entertainment, NSFW AI chatbots provide a unique and private way to explore personal fantasies. From CrushOn.AI's personalized models to Janitor AI's light-hearted chats, there's a platform for every desire. When selecting your preferred NSFW AI chatbot, consider the type of interaction, customization options, and the community involved to find your perfect virtual companion. Frequently Asked Questions About NSFW AI Chatbots 1. What is an NSFW AI chatbot? NSFW AI chatbots are artificial intelligence-driven platforms designed for users to engage in conversations with a more risqué or user nature. 2. Are NSFW AI chatbots safe to use? Yes, these chatbots provide a secure environment for users to explore and express themselves freely, with privacy and safety measures in place. 3. Can I customize my NSFW AI chat experience? Most NSFW AI chat platforms offer extensive customization options, allowing you to tailor the appearance, personality, and conversation style of your AI chatbot. 4. Are there free NSFW AI chatbots? Some NSFW AI chatbots offer free versions with basic features, while others require a subscription for full access to all functionalities. 5. How do I choose the best NSFW AI chatbot? Consider what you're looking for in terms of interaction style, customization, and community engagement. Reading reviews and trying out different platforms can help you decide which NSFW AI chatbot suits your needs best. By meticulously crafting this review with user engagement and keyword optimization in mind, we aim to satisfy both the curiosity of potential users and the technical requirements for higher search rankings. The NSFW AI chatbot industry promises a tantalizing blend of technology and titillation, ensuring that the digital realm remains an endlessly fascinating frontier for entertainment. Contact Details CrushonAI Business business@crushon.ai

January 22, 2024 06:38 AM Eastern Standard Time

Image

Social Network Whitepaper Introduces Bitcoin Staking and Layer 2 Protocol, Aiming to Scale Bitcoin

Earth Wallet

Social Network is the first decentralized Layer 2 Bitcoin Staking Protocol, has unveiled a whitepaper outlining a solution to address the scalability, cost-efficiency, and environmental sustainability of the Bitcoin network. By harnessing recent upgrades in Bitcoin, Ethereum, and the Nostr Protocol, this system addresses the challenges of high transaction fees and slow confirmations on Bitcoin, aiming to bring the scalability of social networks to the blockchain without relying on centralized intermediaries. The integration of Bitcoin Taproot Script with Ethereum Validators allows for efficient bundling of transactions into succinct zero-knowledge proofs, reducing the strain on the Bitcoin blockchain. In addition, the inclusion of Nostr ensures a trustless and efficient relay for large-scale data storage and availability of Bitcoin transactions. Everhusk, the author of the protocol, presents a solution to revolutionize the Bitcoin ecosystem. The goal is to make Bitcoin more scalable, cost-effective, and resilient to congestion, ultimately unlocking the potential for decentralized social networks on both Bitcoin and Ethereum. Sukhveer Sanghera, a long-time Bitcoin and Ethereum contributor, expressed his excitement about the project's future, stating, "The whitepaper marks the start of an exciting journey. Congestion on the Bitcoin Network from Ordinals and other media is a real problem, and by integrating with the Nostr protocol, we are excited to finally bring a real scaling solution to Bitcoin that can ultimately allow us to have decentralized social networks. The goal is to help our planet earth, and decentralizing social networks by scaling Bitcoin is the first step in a better earth for all.” For those interested in exploring the full whitepaper and gaining a deeper understanding of Social Network's approach, please visit social.network. About Social Network: Social Network Bitcoin Layer 2 is the first decentralized Layer 2 Bitcoin Staking protocol, providing a more scalable, cost-efficient, and greener Bitcoin network. With Social Network users have the ability to stake their BTC without any limits, enjoy instant withdrawals, benefit from competitive fees, and experience full decentralization with self-custody. The Social Network Bitcoin Layer 2 aims to lower transaction fees and data storage demands, enabling decentralized social networks to scale while reducing energy consumption for the Bitcoin network and benefiting the planet earth. Website | Twitter | Discord Contact Details Dan Edelstein PR@marketacross.com

January 22, 2024 05:27 AM Eastern Standard Time

News Release

Top 4 Spinal Injury Stocks for 2024 (NRX.V, NVRO, SYK, BSX)

CGR Spine

Investors eyeing dynamic opportunities in healthcare should take note of the burgeoning growth anticipated in the spinal cord injury market. Projections for robust advancements, driven by enhanced diagnosis and increased global healthcare spending, signal a lucrative trajectory from 2023 to 2032, with a significantly positive CAGR, according to Delveinsights. With the spinal cord injury market showing promising growth, let's explore key stocks that could offer potential returns in the evolving healthcare landscape. NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) is positioned as a pioneering force in biopharmaceuticals, with a primary focus on advancing the field of biologically-guided exosome therapy for traumatic spinal cord injuries. Founded on innovative technology, NurExone's flagship product, ExoPTEN, stands out as a potential game-changer. Administered intranasally, ExoPTEN represents a minimally invasive ExoTherapy designed to induce neuron regeneration and rewiring in traumatically damaged spinal cords. The company holds exclusive worldwide licenses from the Technion and Tel Aviv University, signifying its leadership in translating groundbreaking concepts into actionable solutions. Key milestones in NurExone's journey include a notable Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA). This crucial interaction, held on August 29, 2023, provided clear guidance for the manufacturing, preclinical, and clinical development plans of ExoPTEN. The FDA's endorsement of NurExone's proposed ExoPTEN release testing strategy and toxicity study strategy sets the stage for submitting an Investigational New Drug (IND) application by Q4 2024, with Phase 1/2 human clinical studies anticipated to commence in 2025. In tandem with its commitment to acute spinal cord injury treatments, NurExone secured a $1 million New Israeli Shekels grant from the Israel Innovation Authority. This grant fosters collaboration with Inteligex Inc. to develop an innovative hybrid therapy targeting chronic spinal cord injuries. The collaboration, approved by the Israel-Canada bilateral Eureka program, broadens NurExone's potential market focus. The FDA's grant of Orphan-Drug Designation (ODD) for ExoPTEN therapy on October 30, 2023, marks a pivotal milestone. This designation recognizes the therapy's potential impact on acute spinal cord injuries, offering NurExone significant benefits such as market exclusivity, financial incentives, and regulatory support. The ODD status streamlines the company's go-to-market strategy, signaling a promising path for ExoPTEN. NurExone's commitment to continuous innovation is evident in its laboratory tests unveiled on November 29, 2023. These tests showcased two proprietary small inhibiting RNA sequences targeting the Peri-Neural Network (PNN) complex, representing a significant advancement in spinal cord injury treatment. The potential for two new products in the company's portfolio underscores NurExone's dedication to diversifying its molecular arsenal. The company's financial vitality received a boost with the closure of a non-brokered private placement on January 5, 2024. Raising CAD$1,985,758.04, this investment reflects strong investor confidence in NurExone's technology and direction. The proceeds are earmarked for advancing development activities, expanding the intellectual property portfolio, and supporting overall corporate objectives. More recently, on January 17, 2024, NurExone's collaborative agreement with Inteligex Inc. was officially underway. This collaboration aims to combine Inteligex's expertise in cell-based therapies with NurExone's innovative exosome platform, focusing on developing therapies for chronic spinal cord injuries. Additionally, NurExone has entered into an agreement with bullVestor Medien GmbH to enhance awareness of its products in German-speaking countries. NurExone Biologic Inc. is at the forefront of biologically-guided exosome therapy, supported by a number of milestones and technological advancements. The journey from FDA interactions to collaborative partnerships and financial investments paints a comprehensive picture of NurExone's trajectory, positioning the company as a leader in reshaping the landscape of regenerative therapies for spinal cord injuries. Nevro Corporation (NYSE: NVRO), headquartered in Redwood City, California, stands at the forefront of the medical device industry, specializing in transformative solutions for chronic pain treatment. Focused on their mission to alleviate debilitating pain, Nevro developed the groundbreaking 10 kHz Therapy—an evidence-based, non-pharmacologic innovation that has positively impacted over 100,000 patients worldwide. One notable achievement is the publication of 24-month data from the SENZA Nonsurgical Refractory Back Pain (NSRBP) trial in the Journal of Neurosurgery: Spine. This trial demonstrated the profound benefits of Nevro's high-frequency spinal cord stimulation (SCS) system in managing chronic back pain. Patients experienced significant pain relief, improved function, and enhanced quality of life, with a noteworthy reduction in opioid usage. Moreover, Nevro's strategic acquisition of Vyrsa Technologies expands its portfolio to address chronic sacroiliac joint pain—an essential move in a market valued at over $2 billion and expected to witness double-digit growth. This acquisition positions Nevro to offer tailored therapies, driving long-term shareholder value and contributing to growth projections in 2024. The company's financial performance, highlighted in the fourth-quarter 2023 results, exceeded expectations, showcasing consistent growth and a focus on key pillars: commercial execution, market penetration, and profit progress. Despite a restructuring initiative, Nevro remains committed to innovation, as evidenced by its partnership with Carelon Healthcare to broaden spinal cord stimulation coverage for painful diabetic neuropathy. As Nevro continues to pioneer advancements in chronic pain treatment, its comprehensive solutions and strategic initiatives position it as a key player in the evolving landscape of medical device innovation. Stryker Corporation (NYSE: SYK), a trailblazer in the medical technology domain, recently achieved a historic milestone, surpassing $20 billion in annual sales for the first time in December 2023. This achievement underscores Stryker's global impact on over 130 million patients annually and solidifies its position as a major leader in the medical device industry. Specializing in MedSurg, Neurotechnology, Orthopaedics, and Spine, Stryker stands out for its commitment to innovation and improving healthcare outcomes. In the realm of spine-related technology, the company's Spine division has demonstrated notable advancements, showcasing a dedication to state-of-the-art solutions for surgeons and patients alike. Robbie Robinson, President of the Spine division, emphasized the company's exciting year with multiple product launches, highlighting the continued growth of the Spine business. Among these launches, the Q Guidance System with Spine Guidance Software stands out, receiving the prestigious 2022 Best Technology in Spine award for its contributions to surgical spine planning and navigation. Stryker's commitment to excellence is further evident in products like the Monterey AL Interbody System, incorporating Tritanium In-Growth Technology, and the Bone Mill+, designed for enhanced efficiency in bone milling. The OmniCurve curved balloon system adds another dimension to Stryker's offerings, providing surgeons with advanced capabilities and control. As Stryker achieves record-breaking financial success, its continuous innovation in spine-related technology positions the company as a key player with substantial potential in the medical device sector. Stay tuned for more insights into Stryker's financial results during its upcoming Q4 and full-year earnings call on January 30, 2024. Boston Scientific (NYSE: BSX), a global medical technology leader, has been at the forefront of transforming lives through innovative medical solutions for over 40 years. With a commitment to advancing science and addressing unmet patient needs, the company provides high-performance solutions that enhance healthcare outcomes. In a significant move, Boston Scientific recently completed the acquisition of Relievant Medsystems Inc., marking a milestone in its chronic pain portfolio. Relievant is renowned for its Intracept Intraosseous Nerve Ablation System, the only FDA-cleared therapy for vertebrogenic pain, a form of chronic low back pain. This acquisition strengthens Boston Scientific's position in advanced interventional chronic pain treatments, offering physicians a comprehensive selection of evidence-based options. The Intracept system utilizes basivertebral nerve ablation therapy and has garnered national coverage from major insurers like Anthem Blue Cross Blue Shield and Humana. These coverage expansions, along with existing agreements with Cigna Healthcare and local Medicare plans, significantly increase access to intracept treatments for over 150 million lives. Jim Cassidy, President of Neuromodulation at Boston Scientific, expressed enthusiasm about the revolutionary therapy's potential to help more people suffering from chronic pain. The acquisition, involving an $850 million upfront cash payment and additional contingent payments based on sales performance, is poised to enhance Boston Scientific's capabilities in addressing multiple pain targets. This strategic move reflects Boston Scientific's commitment to offering physicians and patients a diverse range of evidence-based treatment options, further solidifying its position as a leader in the evolving landscape of chronic pain solutions. Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, or assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. Capital Gains Report (CGR), owned by RazorPitch Inc., is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR has been retained by Awareness Consulting to produce and distribute this content related to NRX. As part of that content, readers, subscribers, and webs are expected to read the full disclaimers and financial disclosure statement that can be found on our website capitalgainsreport.com All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR is not a fiduciary by virtue of any persons use of or access to this content. Contact Details CapitalGainsReport Mark McKelvie +1 585-748-6862 markrmckelvie@gmail.com

January 22, 2024 05:00 AM Eastern Standard Time

News Release

4 Of The Best Gold Stocks For 2024

CGR Gold

In December 2023, gold prices soared to an all-time high of $2,135.39/oz, propelled by a weakening U.S. dollar and anticipation of Federal Reserve rate cuts. As we continue into 2024, the focus shifts to the Fed's interest rate decisions, which are expected to be pivotal factors influencing gold prices. Forecasts indicate a short-term dip in gold prices, followed by a resurgence and an anticipated peak at $2,300/oz in 2025, according to JP & Morgan, setting the stage for a potentially lucrative year for gold. For investors eyeing gold's promising trajectory, gold mining stocks offer a unique entry point. These stocks provide a pathway to tap into the gold market's potential. Now, let's delve into four notable mining stocks that could benefit from rallying gold prices Collective Mining Ltd. (OTCQX: CNLMF) (TSX: CNL) is making significant progress in the exploration sector, with an emphasis on gold, silver, copper, and tungsten projects in Caldas, Colombia. Collective Mining, founded by the team that successfully sold Continental Gold Inc. to Zijin Mining for approximately $2 billion, is notable for its projects in a proven mining camp with ten fully permitted and operational mines nearby. The Guayabales flagship project revolves around the Apollo target, a substantial gold-silver-copper-tungsten porphyry system that comes directly to surface. As of 2023, Collective Mining had completed 92 drill holes, covering approximately 40,000 meters, with pending assay results. Highlight holes include 519 meters at 2.76 g/t gold equivalent and 503 meters at 2.02 g/t gold equivalent, both of which began from surface. The company has ambitious plans for 2024, aiming to deploy up to six rigs throughout the year and drill more than 40,000 metres. In 2024, Collective Mining's primary objectives include expanding the Apollo System, known for its robust gold-silver-copper-tungsten porphyry system. The company will also focus on exploring early-stage targets along the 4.5-kilometer porphyry corridor at Guayabales. Notable targets include Olympus, Trap, Plutus, Target X, and Tower Target. Last week, Collective announced a new major discovery at the Trap target, located northeast of the Apollo porphyry system. A sizable and consistent zone of precious metal mineralization was found in two diamond drill holes. It is thought to be the upper part of a porphyry system with even better potential below. Drill hole TRC-2 intercepted 646.0 meters at 0.81 g/t gold equivalent, including 301.5 meters at 1.01 g/t gold equivalent, while TRC-3 revealed multiple intervals of continuous mineralization. This is a remarkable start to a grass-roots discovery. Collective Mining's Executive Chairman, Ari Sussman, expressed enthusiasm about the discoveries at Guayabales, highlighting the company's aggressive exploration approach. With its 2024 drill program set to be the most ambitious yet, Collective Mining positions itself as a compelling player in the dynamic world of mineral exploration. As the company resumes drilling at Trap, investors await further assay results, anticipating a deeper understanding of this significant discovery. The ongoing success at Guayabales solidifies Collective Mining's position as a noteworthy player in the exploration sector. Aris Mining Corporation (TSX: ARIS) (NYSE-A: ARMN) stands tall in the gold mining landscape, strategically positioned in the Americas. Operating in Colombia and Guyana, Aris Mining achieved noteworthy success in 2023, producing 226,151 ounces of gold within the projected range of 220,000 to 240,000 ounces. CEO Neil Woodyer highlighted the company's accomplishments, emphasizing the fulfillment of production guidance at Segovia Operations and the ongoing operations of Marmato Upper Mine during the construction of the new Marmato Lower Mine. Anticipating a total gold production between 220,000 and 240,000 ounces in 2024, Aris Mining is steadfast in its growth trajectory. Aris Mining's expansion initiatives include enhancing the Segovia processing facility by 50% to 3,000 metric tons per day by early 2025. Simultaneously, the construction of the Marmato Lower Mine is underway, with the first gold pour expected in late 2025. With aspirations to produce around 500,000 ounces of gold in Colombia in 2026, Aris Mining solidifies its long-term vision. Key highlights from 2023 include consistent quarter-over-quarter increases in gold production, Segovia Operations achieving an AISC/oz of $1,139 for the nine months ending September 30, 2023, and substantial increases in mineral resource and reserve estimates. Aris Mining's exploration plans for 2024 involve a strategic investment of $21 million to capitalize on prior successes at Segovia Operations, aiming for further resource expansion. With a conscientious focus on responsible and formalized artisanal and small-scale mining, Aris Mining not only excels in production but also distinguishes itself through ethical and sustainable practices. The company's exploratory endeavors, strategic initiatives, and growth-oriented commitment position it as a pivotal force in the dynamic landscape of gold mining in the Americas. Barrick Gold Corporation (NYSE: GOLD) stands as a prominent figure in the gold and copper industry, recently disclosing preliminary production figures for both the full year and the fourth quarter of 2023. Despite facing challenges, such as equipment issues in the Dominican Republic mine and reduced output in the Nevada Gold Fields project, Barrick's full-year gold production reached 4.05 million ounces. Notably, the company experienced a sequential increase in the fourth quarter, with gold production hitting 1.05 million ounces. Copper production for the year stood at 420 million pounds, maintaining consistent performance across all three production sites. This performance, however, did not meet earlier forecasts, resulting in a 2.17% decline in annual gold production. In response to these challenges, Barrick showed tenacity by reporting increases in Q4 gold production, which were driven by strong performances at key sites. Looking ahead, the company anticipates an 8% to 10% increase in all-in sustaining costs (AISC) per ounce of gold. In contrast, copper's AISC is projected to be 2% to 4% lower than the previous quarter. Leadership remains a key focus, with President and CEO Mark Bristow set to lead the upcoming presentation on February 14, 2024. Barrick's overarching purpose is to build the world's most valued gold and copper company, emphasizing high-margin, long-life assets managed by the best people. As investors navigate the dynamic landscape of mining stocks in 2024, Barrick Gold Corporation offers a compelling narrative, showcasing resilience in the face of challenges and providing a strategic outlook for the future. The upcoming quarterly report presentation promises a deeper understanding of Barrick's financial health and growth prospects. Newmont Corporation (NYSE: NEM), with a rich history spanning over a century, holds the distinction of being the largest gold-mining stock based on market capitalization and stands as the sole gold producer included in the S&P 500. The company's appeal has significantly increased following the completion of its acquisition of Newcrest in November. This strategic move is anticipated to bring immediate value, with Newmont projecting $500 million in pre-tax synergies over the two years following the deal's closure. Additionally, the company aims for a minimum of $2 billion in cash improvements through portfolio optimization during the same period. Examining Newmont's cash flow potential, the company reported operating cash flow of $1 billion for Q3 2023. With the combined impact of a higher gold price and the benefits derived from the acquisition, Newmont is poised for an operating cash flow exceeding $5 billion in 2024. Recently, the company disclosed its plan to release full-year and fourth-quarter 2023 operations and financial results, along with 2024 guidance, on Thursday, February 22, 2024. Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, or assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. Capital Gains Report (CGR), owned by RazorPitch Inc., is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR has been retained by Collective Mining Ldt to produce and distribute this content. As part of that content, readers, subscribers, and webs are expected to read the full disclaimers and financial disclosure statement that can be found on our website capitalgainsreport.com All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR is not a fiduciary by virtue of any persons use of or access to this content. Contact Details CapitalGainsReport Mark McKelvie +1 585-301-7700 markrmckelvie@gmail.com Company Website http://CapitalGainsReport.com

January 22, 2024 05:00 AM Eastern Standard Time

ApeX Protocol Unveils Trade-to-Earn Round 2 with Enhanced Rewards Pool & Extra Layers of Incentives

ApeX

ApeX Protocol, a leading player in the cryptocurrency trading space and one of the top non-custodial derivatives decentralized exchanges (DEX), is thrilled to announce the highly anticipated launch of Trade-to-Earn (T2E) Round 2 as of January 22, 2024. Following the success of the inaugural event in November 2022, T2E Round 2 promises an even more rewarding experience for ApeX traders with enhanced incentives and a revamped rewards structure. T2E is a 52-week long program where traders can earn rewards based on their trading activity. The more trades executed, the greater the rewards accumulated. This year, ApeX is introducing exciting updates to make the journey even more rewarding for participants. Key Highlights of T2E Round 2: Introduction of $BANANA Token: T2E Round 2 is facilitated by a new $BANANA token on the Ethereum network. A total of 10,000,000 $APEX is locked over a 12-month period to mint $BANANA, at an initial redeem rate of 0.001. Reward tokens, distributed automatically on a bi-weekly basis, will be granted to users trading USDT perpetual contracts on ApeX Pro. Enhanced Rewards Pool with Potential Airdrop Opportunities: T2E Round 2 introduces an enhanced rewards pool, providing extra layers of incentives and benefits for ApeX traders with potential airdrop opportunities. In addition to $BANANA rewards, participants have the opportunity to claim rewards in partner project tokens. The distribution of airdrop rewards will be determined by traders' activities (T2E score) and project-specific factors in the coming months. Maximizing Rewards in 3 Steps: Swap: $BANANA can be easily swapped for USDT via the $BANANA-USDT pool at any time during the 52 weeks. Add Liquidity: By adding $BANANA and USDT to the $BANANA-USDT Pool, traders can acquire LP Tokens. Greater LP token holdings result in amplified $BANANA rewards at the conclusion of each epoch. Hold and Redeem: Holders of $BANANA can redeem $APEX governance tokens on a pro-rata basis after the event period. Acquired $APEX can be utilized in ApeX's revenue-sharing program through staking, further enhancing users' holdings with an additional passive income-generating tool on ApeX. Creating Value for the Community T2E events are aligned with the principles of crypto and decentralized finance, aiming to reciprocate to the community by enabling them to grow their wealth in a fair, transparent, and rewarding manner. Tekla I, the Head of Business Development at ApeX Protocol, expressed her enthusiasm about the launch: "We are excited to welcome traders back for the second iteration of Trade-to-Earn. T2E Round 2 is a testament to our commitment to providing our community with innovative and rewarding opportunities in the crypto space. At ApeX, we believe in the synergy between decentralization and community. T2E Round 2 is our way of rewarding our community for their contributions and dedication to our platform." About ApeX ApeX is a permissionless and non-custodial derivatives decentralized exchange, powered by StarkWare's Layer 2 scalability engine StarkEx, delivering USDC and USDT cross-margined perpetual contracts with over 30 trading pairs and up to 50x leverage. It is primed to provide permissionless access to the perpetual swaps market with its order book model, as it remains committed to the promises of speed, efficiency, and security with transparency on traders' preferred derivatives trading assets. Website | Twitter | Discord | Telegram | Blog Contact Details Mariam I mariam@davionlabs.com

January 22, 2024 04:54 AM Eastern Standard Time

Image

RZ Publish Nooro Foot Massager Reviews: Why It Is Used In The United States?

Spark Metro

Are you tired of living with constant burning and tingling in your feet due to neuropathy? Frustrated with painkillers that merely numb the discomfort without addressing the root cause? If so, you're not alone. Many have experienced the struggle of seeking relief from neuropathic pain, only to find temporary solutions. However, you are lucky to have come across this review because it is a comprehensive report about a breakthrough device popularly known as Nooro Foot Massager that goes beyond masking the symptoms, offering a chance to reverse nerve damage and regain a life free from persistent foot pain. In a world where traditional remedies may involve uncomfortable movements, Dr. Jeremy Campbell, in collaboration with the innovative med tech startup Nooro, introduces Nooro Foot Massager as a simple at-home solution for foot pain powered by Neuromuscular Electrical Stimulation (NMES) technology. This is where the story takes a turn towards hope and healing. Are you ready to break free from neuropathic pain and experience the relief you've been longing for? The Nooro Foot Massager might just be your key to a new lease on life. What Is Nooro Foot Massager? Nooro Foot Massager is a revolutionary at-home solution developed through the collaboration of Dr. Jeremy Campbell and the innovative med tech startup, Nooro. Designed to address neuropathic foot pain, Nooro Foot Massager device employs NeuroMuscular Electrical Stimulation (NMES) technology to offer relief in the comfort of your home. Specifically named the Nooro Foot Massager, this device stands out by delivering a unique combination of targeted electric impulses deep into the tissues of your feet and legs. The primary goal? To kickstart blood circulation, a crucial factor in providing the oxygen necessary for nerve recovery. By enhancing blood flow to your feet, the Nooro Foot Massager becomes a catalyst for nerve repair and healing. This breakthrough approach holds the promise of reducing the burning pain, tingling, and numbness associated with neuropathy. The ultimate result? A chance to reclaim the activities you love, free from the constant foot pain and swelling that may have confined you. This user-friendly device opens doors to a life where neuropathic pain no longer dictates your daily experiences, offering a pathway to comfort and mobility. In essence, the Nooro Foot Massager is more than just a device – it's a transformative tool designed to empower you on your journey to relief from neuropathic foot pain. CLICK HERE NOW TO GET THE NOORO FOOT MASSAGER DIRECTLY FROM THE OFFICIAL WEBSITE Features (Nooro Foot Massager Reviews USA) EMS Technology: The Nooro Foot Massager employs advanced NeuroMuscular Electrical Stimulation (EMS) technology. This technology facilitates the penetration of steady electric impulses deep into the tissues of the feet and legs, aiming to relieve muscle tension, increase blood circulation, and strengthen weakened muscles. Cordless Convenience: The Nooro EMS Foot Massager offers a cordless design, eliminating the hassle of dealing with tangled cords during use. Charging is simple using the provided electricity plug and cable, ensuring a convenient and clutter-free experience. Optional Preparatory Step: While optional, the recommendation to wash your feet and remove excess skin before using the massager adds a thoughtful touch. This preparatory step enhances the overall effectiveness of the massage treatment, promoting a more thorough and satisfying experience. Versatile Massage Modes: The device features a variety of different modes, providing users with options to cater to their specific needs. Whether you're looking to relax after a long day or target particular muscle groups causing discomfort, the Nooro Foot Massager's versatility ensures a customized and enjoyable experience. Adjustable Intensity Levels: Tailoring the massage experience to individual preferences, the massager offers a mind-bending number of speed settings. This wide range allows users to find the perfect intensity level, ensuring that the massage is both effective and comfortable for various muscle groups. User-Friendly Operation: The massager's simplicity is a standout feature. With easy-to-follow steps—place your feet on the foot pad, select the mode, and adjust intensity—you can initiate the massage effortlessly. The user-friendly design ensures that anyone can enjoy the benefits without a steep learning curve. Effective Neuropathy Relief: The Nooro Foot Massager is specifically designed to address neuropathic foot pain. By enhancing blood circulation, relieving muscle tension, and providing a targeted massage experience, the device aims to alleviate burning pain, tingling, and numbness. Users can experience liberation from the challenges of neuropathy, promoting overall foot health and well-being. Benefits Of Nooro Foot Massager Pain Alleviation: A primary benefit of the Nooro Foot Massager is its ability to ease neuropathic foot pain. By employing advanced EMS technology, the massager delivers targeted electric impulses to alleviate burning sensations and discomfort associated with neuropathy. Users may experience significant relief from persistent foot pain. Tingling Relief: This innovative EMS massager targets nerve-related tingling sensations by enhancing blood circulation. Through its unique combination of electric impulses, the Nooro Foot Massager aims to improve oxygen supply to peripheral nerves, reducing tingling and promoting a sense of comfort. Numbness Reduction: For individuals experiencing numbness due to neuropathy, the Nooro Foot Massager offers hope. By increasing blood flow to the feet and facilitating nerve repair, the device strives to reduce numbness, allowing users to regain sensation in their extremities. Improved Blood Circulation: A core benefit lies in the massager's ability to enhance blood circulation. The EMS technology stimulates blood flow to the feet and legs, ensuring a continuous supply of oxygen to nerve cells. Improved circulation contributes not only to pain relief but also to overall foot health. Muscle Strengthening: Beyond addressing neuropathic pain, the Nooro Foot Massager helps strengthen weakened muscles. The electric impulses penetrate deep into the tissues, promoting muscle stimulation. This additional benefit contributes to overall foot strength and may aid in preventing future discomfort. Convenience and Comfort: The cordless design, along with the straightforward operational steps, adds a layer of convenience to the user experience. The Nooro Foot Massager provides a hassle-free solution for those seeking comfort and relief. Users can enjoy the benefits of a personalized massage without the inconvenience of cords or complicated setup. How Does Nooro Foot Massager Work? (Nooro Foot Massager Reviews) The Nooro EMS Foot Massager operates on advanced EMS (Electrical Muscle Stimulation) technology, offering a multi-faceted approach to relieving discomfort. True to its name, using this device is as simple as placing your feet on it and letting it work its magic. Specifically, Nooro EMS Foot Massager works by increasing blood flow to your feet, the massager facilitates the delivery of much-needed oxygen to nerve cells. This groundbreaking approach opens the door to nerve repair and healing, reducing burning pain, tingling, and numbness. But here's the beauty of it – as long as your nerves are alive, there's hope for reversal. The National Institute of Health emphasizes the regenerative capacity of peripheral nerves when the underlying nerve cell remains intact. The Nooro Foot Massager becomes a tool for revitalization, offering relief and a chance to reclaim a life without constant foot pain. This innovative massager employs steady electric impulses that penetrate deep into your feet and legs, effectively targeting muscle tension. The result? Relaxation of tense muscles, which is essential for alleviating discomfort associated with neuropathic foot pain. What sets the Nooro Foot Massager apart is its versatility. With a variety of modes and an impressive array of speed settings, the device allows you to tailor your experience to address specific muscle groups. This flexibility ensures that you can find a satisfying combination, catering to the unique needs of whatever muscle group is causing you distress. In essence, the Nooro Foot Massager is designed to be user-friendly and customizable. Its cutting-edge EMS technology aims to enhance blood circulation, relieve muscle tension, and strengthen weakened muscles, all while providing a hassle-free experience. So, whether you're looking to unwind after a long day or target specific muscle groups causing discomfort, this device offers a personalized solution to meet your needs. Who Needs Nooro Foot Massager? Foot Pain and Discomfort: If your feet hurt or feel uncomfortable, the Nooro Foot Massager can give you relief and make you feel better. Plantar Fasciitis: If you have plantar fasciitis (pain in the bottom of your feet), using the massager can help ease the pain and make your feet more comfortable. Athletes and Runners: Athletes and runners can use the massager to relax their muscles and recover faster after exercising. Diabetes: If you have diabetes and your feet need extra care, the Nooro Foot Massager can be part of your routine to keep your feet comfortable. Swelling: If your feet are swollen, especially during pregnancy or due to certain health issues, the Nooro Foot Massager can help reduce the swelling. General Well-being: If you just want to feel better overall and more relaxed, using the Nooro Foot Massager can contribute to your well-being. CLICK HERE NOW TO GET THE NOORO FOOT MASSAGER DIRECTLY FROM THE OFFICIAL WEBSITE AT A MASSIVE DISCOUNT Does Nooro EMS Foot Massager Really Work? Absolutely, the Nooro EMS Foot Massager has garnered positive reviews from satisfied customers, attesting to its effectiveness. Users express genuine satisfaction with the relief it provides, particularly in addressing knee-related concerns. Many have reported that it contributes to a positive sensation in their knees, offering comfort and support, especially before bedtime. Customers dealing with foot pains have found solace in the Nooro Foot Massager. The device seems to provide tangible relief, soothing discomfort associated with foot pains. The positive feedback highlights the impact of the massager in helping alleviate foot-related issues, making it a promising solution for those seeking relief from foot pain. One user shared their experience, noting the immediate positive effects after just one use. This firsthand account emphasizes the rapid and noticeable benefits users can expect, further reinforcing the idea that the Nooro EMS Foot Massager indeed works to bring comfort and relief. In essence, the testimonials from customers reflect a consensus that the Nooro EMS Foot Massager is not just a device but a reliable solution that genuinely addresses pain and discomfort, particularly in the knees. The positive feedback from users reinforces the notion that the Nooro Foot Massager is effective in delivering the relief it promises. How To Use Nooro Foot Massager? Using the Nooro EMS Foot Massager is delightfully straightforward, making it a hassle-free addition to your routine. First and foremost, you'll appreciate the absence of annoying cords – charging is a breeze with the included electricity plug and cable that come with your order. Once charged, the process is as simple as 1-2-3. For an optimal experience, the second step is optional but recommended – give your feet a quick wash and remove any excess skin. This preparatory step significantly enhances the effectiveness of the massage treatment. Now, you're ready to indulge in the soothing benefits of the Nooro Foot Massager. Just place your feet on the foot pad, select your preferred mode, and adjust the intensity level of the massage to your liking. It's a customizable experience tailored to meet your unique needs. From there, all that's left to do is sit back comfortably and let the massager work its magic. As it eases pain, relieves tingling, and liberates you from the challenges of neuropathy, you'll find a newfound sense of comfort and relief. The Nooro Foot Massager brings simplicity and effectiveness together, making it a user-friendly solution for those seeking relief from neuropathic foot pain. Price Of Nooro Foot Massager And Where To Buy Nooro Foot Massager can be gotten directly from the manufacturer’s official website at the following prices: Single Unit: Buy one Nooro Foot Massager for $99.95. Two Units: Buy two Nooro Foot Massagers for $94.95 each. Total cost: $189.90. Three Units: Buy three Nooro Foot Massagers for $89.95 each. Total cost: $269.85. Four Units: Buy four Nooro Foot Massagers for $87.95 each. Total cost: $351.80. Six Units: Buy six Nooro Foot Massagers for $84.95 each. CLICK HERE NOW TO GET THE NOORO FOOT MASSAGER DIRECTLY FROM THE OFFICIAL WEBSITE Nooro Foot Massager Reviews Consumer Reports And Customer Complaints The Nooro EMS Foot Massager has received overwhelmingly positive consumer reports, with an impressive 4.8-star rating and a noteworthy achievement of zero customer complaints. Thousands of individuals have experienced successful outcomes in reversing neuropathy with this device, highlighting its efficacy and customer satisfaction. Harry Keegan - “Superb relaxation, it's not bulky, so you can take it anywhere, cheaper than other massagers, does what it says. You'll love the "cupping mode". Many intensity options (up to 19). It's a great product with fast shipping! My wife loves it…” Debra Peyton - “Should have bought Nooro Foot Massager earlier, exactly what I needed for my neuropathy-pained-feet. Honestly, I can walk and move with just minimal pain. I've only used it for like 2 days and I have felt better than I have in the past 2 years!!!” Clara Milton - “I absolutely love my Nooro EMS Foot Massager massager, had to get one for my daughter today since she wont stop using mine!” Final Verdict On Nooro EMS Foot Massager Reviews The overwhelming positive reviews and testimonials for the Nooro Foot Massager paint a compelling picture of its effectiveness and customer satisfaction. With a remarkable 4.8-star rating and zero customer complaints, it stands out as a reliable solution for those seeking relief from neuropathic foot pain. Customers like Harry Keegan commend the massager for its superb relaxation, portability, affordability, and diverse intensity options. The mention of the "cupping mode" adds to the device's appeal. Debra Peyton's experience reinforces the quick and tangible relief the Nooro Foot Massager provides, enabling her to walk with minimal pain after just two days of use. Clara Milton's enthusiasm and the decision to purchase an additional massager for her daughter further underscore the positive impact and effectiveness of the device. In the final verdict, the Nooro Foot Massager emerges as a standout product, praised for its user-friendly design, versatility, and ability to address neuropathy-induced foot pain. The absence of customer complaints reinforces its credibility, making it a promising choice for those in search of a reliable and effective solution to neuropathic pain. CLICK HERE NOW TO GET THE NOORO FOOT MASSAGER DIRECTLY FROM THE OFFICIAL WEBSITE Disclaimer: Please understand that any advice or guidelines revealed here are not even remotely substitutes for sound medical or financial advice from a licensed healthcare provider or certified financial advisor. Make sure to consult with a professional physician or financial consultant before making any purchasing decision if you use medications or have concerns following the review details shared above. Individual results may vary. These products are not intended to diagnose, treat, cure or prevent any disease and do not provide any kind of get-rich money scheme. Reviewer is not responsible for pricing inaccuracies. Check product sales page for final prices. Contact Details Review Zenith Alex +1 302-597-6768 Apexreviews154@gmail.com Company Website https://reviewzenith.com/

January 22, 2024 04:37 AM Eastern Standard Time

Image

All Industries

Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA

Trust & Will Bolsters Executive Team with Strategic Hires

Mercury/13 Unveils Co-CEO Alliance: Mario Malavé and Victoire Cogevina Aim to Transform Women's Football Club Ownership

Top NSFW AI Chatbots Ranking Review [Jan 2024]

Social Network Whitepaper Introduces Bitcoin Staking and Layer 2 Protocol, Aiming to Scale Bitcoin

Top 4 Spinal Injury Stocks for 2024 (NRX.V, NVRO, SYK, BSX)

4 Of The Best Gold Stocks For 2024

ApeX Protocol Unveils Trade-to-Earn Round 2 with Enhanced Rewards Pool & Extra Layers of Incentives

RZ Publish Nooro Foot Massager Reviews: Why It Is Used In The United States?